KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $4.6 billion.

  • Pfizer's Cash from Operations fell 2357.63% to $4.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 billion, marking a year-over-year increase of 1709.23%. This contributed to the annual value of $12.7 billion for FY2024, which is 4648.28% up from last year.
  • Per Pfizer's latest filing, its Cash from Operations stood at $4.6 billion for Q3 2025, which was down 2357.63% from -$582.0 million recorded in Q2 2025.
  • Pfizer's Cash from Operations' 5-year high stood at $27.0 billion during Q4 2021, with a 5-year trough of -$1.8 billion in Q2 2024.
  • For the 5-year period, Pfizer's Cash from Operations averaged around $6.2 billion, with its median value being $4.6 billion (2021).
  • As far as peak fluctuations go, Pfizer's Cash from Operations skyrocketed by 21760.9% in 2021, and later plummeted by 11477.5% in 2023.
  • Over the past 5 years, Pfizer's Cash from Operations (Quarter) stood at $27.0 billion in 2021, then decreased by 23.37% to $20.7 billion in 2022, then plummeted by 74.67% to $5.2 billion in 2023, then rose by 14.94% to $6.0 billion in 2024, then fell by 23.58% to $4.6 billion in 2025.
  • Its last three reported values are $4.6 billion in Q3 2025, -$582.0 million for Q2 2025, and $2.3 billion during Q1 2025.